Lonza Completes $4.5-Bn Divestment of Specialty Ingredients Business

By Miranda Greenberg -

July 8, 2021

Lonza has completed the divestment of its former Specialty Ingredients business and operations to Bain Capital and Cinven, two private-equity firms, for an enterprise value of CHF 4.2 billion ($4.5 billion).

Lonza’s Specialty Ingredients business provides microbial control services for professional hygiene and personal-care products and custom development and manufacturing of specialty chemicals and composites to support the electronics, aerospace, food, and agrochemical industries. It operates across 17 manufacturing sites globally and has approximately 2,800 permanent employees.

The divestment positions Lonza as a pure player in the bio/pharmaceutical industry.

The agreement was previously announced in February (February 2021).

Source: Lonza